Gemcitabine & Paclitaxel for unresectable or metastatic bladder cancer

From - A Hematology Oncology Wiki
Jump to: navigation, search

Regimen in use at

Regimen variant #1 - 3-week cycles

Study Evidence Efficacy Pt Population
Meluch et al. 2001 Phase II 54% (95% CI 40-67%) mix of chemo-naive and exposed (but not with gemcitabine or paclitaxel)


21-day cycle for up to 6 cycles

Regimen variant #2 - 2-week cycles

Study Evidence Efficacy Pt Population
Calabrò et al. 2009 Phase II 37% no prior systemic therapy


Supportive medications

14-day cycle for 6 to 12 cycles


  1. Meluch AA, Greco FA, Burris HA 3rd, O'Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001 Jun 15;19(12):3018-24. link to original article PubMed
  2. Calabrò F, Lorusso V, Rosati G, Manzione L, Frassineti L, Sava T, Di Paula ED, Alonso S, Sternberg CN. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009 Jun 15;115(12):2652-9. link to original article contains protocol PubMed